Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
Sell
-59,500
Closed -$5.2M 150
2019
Q4
$5.2M Buy
+59,500
New +$5.08M 0.07% 105
2018
Q3
Sell
-438,000
Closed -$29.3M 156
2018
Q2
$29.3M Buy
+438,000
New +$30M 0.35% 67
2017
Q4
Sell
-1,476,000
Closed -$172M 139
2017
Q3
$172M Sell
1,476,000
-187,400
-11% -$23.7M 1.65% 20
2017
Q2
$209M Sell
1,663,400
-310,197
-16% -$39.5M 2.2% 14
2017
Q1
$264M Sell
1,973,597
-109,203
-5% -$13.9M 2.99% 8
2016
Q4
$209M Buy
2,082,800
+232,622
+13% +$22.7M 2.66% 7
2016
Q3
$174M Sell
1,850,178
-474,500
-20% -$40M 1.99% 13
2016
Q2
$186M Sell
2,324,678
-430,400
-16% -$33.4M 1.94% 15
2016
Q1
$200M Sell
2,755,078
-77,900
-3% -$5.81M 2.1% 13
2015
Q4
$307M Buy
2,832,978
+92,000
+3% +$10.3M 2.78% 11
2015
Q3
$302M Buy
2,740,978
+426,478
+18% +$47.8M 3.05% 10
2015
Q2
$241M Sell
2,314,500
-308,000
-12% -$31.9M 2.02% 18
2015
Q1
$240M Sell
2,622,500
-526,800
-17% -$43.5M 2.05% 16
2014
Q4
$230M Sell
3,149,300
-105,600
-3% -$6.9M 2.2% 14
2014
Q3
$160M Sell
3,254,900
-245,500
-7% -$12.3M 1.67% 22
2014
Q2
$198M Buy
3,500,400
+376,400
+12% +$19.2M 2.32% 15
2014
Q1
$167M Sell
3,124,000
-945,000
-23% -$58.6M 2.06% 17
2013
Q4
$206M Sell
4,069,000
-404,000
-9% -$17.6M 3.03% 7
2013
Q3
$171M Sell
4,473,000
-1,133,000
-20% -$33.4M 3.05% 8
2013
Q2
$123M Buy
+5,606,000
New +$122M 2.61% 11

Other funds holding INCY

OrbiMed's INCY Position: Q1 2020 in Review

OrbiMed sold out of Incyte (INCY) in Q1 2020, closing a stake of 59,500 shares — an estimated $5.2M sold.

OrbiMed first reported a position in INCY in Q2 2013 and held it in 20 quarters. The position peaked at $307M in Q4 2015. 491 funds tracked by Wall St. Rank hold INCY as of Q1 2020.

  • OrbiMed reported no remaining Incyte position as of Q1 2020 after selling out during the quarter.
  • OrbiMed sold 59,500 Incyte shares in Q1 2020, an estimated $5.2M.
  • OrbiMed first reported a position in Incyte in Q2 2013 and held it in 20 quarters.
  • OrbiMed's Incyte position peaked at $307M in Q4 2015.
  • 491 funds tracked by Wall St. Rank held Incyte as of Q1 2020.

Based on OrbiMed's 13F filing for Q1 2020, filed 15 May 2020.